top of page
Search

7 Best Doctors and Centers Offering Clinical Trial Access for Metastatic Breast Cancer in India in 2026

Writer: Ganesh Akunoori
Ganesh Akunoori
7 hours ago
9 min read

Introduction

You have just been told your breast cancer has metastasized. The standard treatment lines are laid out before you, but they may not feel like enough. Your mind immediately races to what else is out there, what is experimental but could be the key to more time, a better response.

You are searching for a doctor, a specific point of contact, who can open the door to a clinical trial. The answer is yes. Specific doctors at major Indian cancer centers offer this access, and their coordinators can directly guide you through the eligibility and enrollment process.

A clinical trial coordinator is your primary point of contact at these research centers. They manage the logistics of a trial, handle the paperwork, and perform the complex eligibility screening against the study's strict inclusion criteria. A patient navigator is a separate support role, often a nurse or social worker, who helps you manage appointments, understand financial obligations, and coordinate travel. They act as your guide through the healthcare system so you can focus on treatment.

One active path in India is Phase 2 trial NCT03606967, sponsored by the National Cancer Institute (NCI). It is currently recruiting 86 participants with metastatic triple-negative breast cancer. This article profiles the key institutions and a specific medical oncologist where clinical trial access for metastatic breast cancer is an active, organized, and accessible part of your treatment plan.

Key Takeaways

Clinical trial access for metastatic breast cancer00212-6) in India sits at a few large research institutions and private centers that have a dedicated oncologist and a patient navigator. Here is what that means for you right now.

  • Direct access is available: Dr. Bharat Patodiya at Pi Cancer Care actively screens and coordinates patient enrollment into trials for metastatic disease.

  • The trial often covers costs: The investigational drug and study-specific procedures are usually paid for by the trial. You may still owe for standard care and hospital stays, but a trial can save ₹5 to 25 lakhs in treatment costs.

  • Major hospitals run trials: Tata Memorial Hospital (ACTREC), AIIMS, and Apollo Proton Cancer Centre carry large portfolios of breast cancer trials you can ask about.

  • India participates in global research: NCI-sponsored studies, like a neoantigen vaccine trial for triple-negative breast cancer (NCT03606967), are recruiting at specialist centers in India.

  • Your first contact matters: You get into a trial by reaching a clinical trial coordinator or a research-integrated medical oncologist directly. A generic registry is not where you start.

1. Dr. Bharat Patodiya, Pi Cancer Care

If you need one doctor to connect you to a clinical trial, start with Dr. Bharat Patodiya at Pi Cancer Care. His clinic screens patients, matches them to active trials, and manages the enrollment paperwork from a single desk.

Screening is the first gate. The team checks your tumor subtype, lines of prior therapy, and organ function against the inclusion criteria of open protocols. When you qualify, Pi Cancer Care handles the monitoring: tumor markers, imaging, and follow-up visits.

The numbers matter here. The centre estimates that a trial cuts treatment costs by ₹5 to 25 lakhs.

Outside a trial, standard oncology packages begin at ₹2.5 to 8 lakhs. You get routed to a financial counsellor who can walk you through Ayushman Bharat PM-JAY eligibility and other aid if the trial sponsor does not cover every charge.

2. Tata Memorial Hospital

Tata Memorial Hospital's Advanced Centre for Treatment, Research and Education in Cancer (ACTREC) in Mumbai is the first place most Indian oncologists send people who have run out of standard breast cancer options. The reason is straightforward: no other centre in the country runs as many clinical trials at once.

The breast cancer research group here runs everything from first-in-human studies to large randomized Phase 3 registration trials. Coordinators embedded in the department handle recruitment from end to end, screening your records against eligibility criteria that shift with every open protocol. A general oncologist does not have the bandwidth or access to do that screening.

Tata Memorial is a public trust hospital, which means its financial model is built to keep out-of-pocket costs down. Government subsidies cover 50 to 70% of treatment expenses. For breast cancer, that brings the typical total to a range of ₹1.5 to 5 lakhs. Even when a trial supplies the investigational drug at no charge, those subsidized standard-care rates quietly remove a big chunk of the financial pressure.

The entry path is narrow and document-heavy. You cannot walk in and ask to join a trial. Your current oncologist must send a referral that includes a complete medical summary, an immunohistochemistry report with hormone and HER2 status, and a record of every prior regimen and how you responded. Once the ACTREC research team receives that packet, they check your fit against the open protocols and reach out to start the consent and screening process.

3. All India Institute of Medical Sciences (AIIMS)

AIIMS, New Delhi, runs clinical trials directly inside its medical oncology department, within a government hospital system where research sits alongside heavily subsidized standard care.

Start at the medical oncology outpatient department. See a consultant and tell them you want an investigational therapy. The oncologist checks your baseline disease status, then refers your file to the clinical research coordinators if you qualify. Those coordinators track an internal registry of open trials, including some that have not appeared yet on ClinicalTrials.gov.

Do not skip the financial counselor. For metastatic disease, your costs split into two buckets. A trial sponsor usually covers the investigational drug. You may still pay for hospitalization, supportive medications, and diagnostic scans. AIIMS financial counselors map out public-private cost splits and help you apply for PM-JAY or state health funds to cover what the sponsor does not.

Expect long wait times for consultations and scheduling. That is the trade-off at a high-volume public hospital. The benefit is access to therapies the private market does not offer, especially large NCI cooperative group trials where AIIMS is a participating site. You get a shot at a next-generation agent years before it reaches an Indian pharmacy.

4. Apollo Proton Cancer Centre

Apollo Proton Cancer Centre in Chennai combines advanced radiation technology with systemic investigational therapies, serving as a practical option for oligometastatic cases. The table below breaks down what to expect when seeking a trial at a technology-integrated private center like Apollo.

Decision Dimension

Apollo Proton Cancer Centre (Integrated Private Model)

Trial Focus & Access

Early-phase trials often combine antibody-drug conjugates (ADCs) or immunotherapy with high-precision proton therapy for limited metastatic disease.

Technology Advantage

Pencil-beam scanning proton therapy delivers tumoricidal doses while minimizing excess radiation scatter to adjacent critical organs.

Patient Eligibility Signal

Typically targets oligometastatic patients where localized ablative radiation can pair with a systemic agent in a protocol setting.

Funding & Support

As a private center, trial-related costs and companion diagnostics may follow a co-pay or sponsor-bundled model rather than fully subsidized care.

Regulatory Pathway

Operates under Indian CDSCO clinical trial regulations; protocol approvals are often faster once an institutional ethics committee signs off.

Screening & Logistics

Requires an on-site or hybrid screening process with a dedicated proton physics consult to verify treatment planning eligibility before enrollment.

5. HCG Cancer Centre

HCG Cancer Centre operates as a multi-city network, which changes your route into a trial. If you live in Bangalore, Ahmedabad, or another city in their hub-and-spoke model, your local HCG oncologist can refer you to a principal investigator at a central trial site. You stay home for routine supportive care.

That referral path cuts out the need to relocate during screening and treatment, which is a real hurdle for many metastatic patients weighing an experimental therapy.

Inside a private network, you have to pull apart the research bill from your regular care bill. The trial sponsor almost always provides the investigational drug at no charge and pays for study-mandated PET-CT scans and biopsies. The costs that stay on your side include in-patient admission for chemotherapy-related neutropenia, anti-emetic protocols (a common example is aprepitant plus dexamethasone and palonosetron), and any imaging the protocol does not require.

Your HCG oncologist and the dedicated clinical research coordinator will walk you through a detailed informed consent form. It spells out those financial lines item by item. Read every line before you sign.

6. Rajiv Gandhi Cancer Institute & Research Centre

Rajiv Gandhi Cancer Institute in Delhi is a charitable trust hospital. For patients in North India who need advanced research but cannot pay private academic center rates, it is one of the few accessible options. Its research programs are notably active in triple-negative breast cancer (TNBC), a subtype that hits younger Indian women disproportionately hard and carries the worst outlook.

The institute's investigators regularly run trials of antibody-drug conjugates and immune checkpoint inhibitors aimed squarely at TNBC. A network meta-analysis published in Frontiers in Oncology pooled data from 3,160 patients across seven ADCs (including T-DM1 and ARX788) and gave a detailed picture of which agents are worth pursuing in pretreated HER2-low disease. That is the kind of agent-specific evidence feeding the trials you might qualify for here. When you have burned through anthracyclines and taxanes, a TNBC trial at a charitable center is often the only realistic path to a next-line therapy.

The staff includes a patient navigator function that solves a concrete problem. The trust's subsidized ward pricing makes treatment affordable, but clinical trials demand scans and documentation that meet rigid sponsor criteria. The navigator helps you use the trust's low-cost imaging while making sure every upload passes the trial's quality checks.

Your approach needs to be tight. Before you call, your biopsy report must spell out ER, PR, HER2, and Ki-67 status. Have your medical oncologist write a one-page summary of every prior regimen with the best response noted for each. Contact the research director's office directly, state your stage and subtype in the first sentence, and ask for a research coordinator callback. The charitable model moves faster when you show up with a complete file; preparation determines how quickly you get triaged.

7. Basavatarakam Indo-American Cancer Hospital & Research Institute

This non-profit institute in Hyderabad runs an Indo-American research collaboration that opens a door to international protocols you won't always find at purely domestic sites. If you have triple-negative breast cancer, an NCI-sponsored Phase 2 neoantigen vaccine trial (NCT03606967) recruiting 86 participants is active here right now, making this hospital a direct entry point for a novel therapy in South India.

  • Personalized immunotherapy: A neoantigen vaccine is not an off-the-shelf drug. It is a personalized immunotherapy built from the mutated proteins your own tumor carries. Your tumor tissue is sequenced to find those unique markers, and the resulting injection is designed to train your immune system to hunt down cancer cells that would otherwise fly under the radar.

  • Managed sequencing: Enrollment in NCT03606967 means the hospital's clinical research staff manages that sequencing process and the biomarker-driven workflow from start to finish.

  • Trust-rate billing: On the cost side, standard hospitalization and supportive care are billed at trust rates, which run substantially lower than corporate hospital pricing. That makes the mandatory hospital visits during a vaccine-based trial easier to plan for.

Conclusion

Access to a clinical trial for metastatic breast cancer in India starts with a single call. You contact a named clinical trial coordinator at one of a handful of centers, not a generic oncology OPD.

The capacity is real. Tata Memorial runs the country's highest-volume portfolio. Pi Cancer Care, where Dr. Bharat Patodiya screens patients directly, enrolls many women who arrive with their entire treatment history in hand. Basavatarakam Indo-American Cancer Hospital recruits for neoantigen vaccine protocols.

Do not wait for a trial to find you. Have your current oncologist prepare a summary of your hormone receptor status, HER2 result, and every prior treatment with its documented response. Send that to the research department at one of these centers and request a screening for an open metastatic breast cancer protocol.

Frequently Asked Questions

How do I find an oncologist who can enroll me in a clinical trial for metastatic breast cancer?

Start by identifying major research-focused cancer centers rather than a solo practitioner. The most direct route is contacting a dedicated clinical trial coordinator at institutions like Tata Memorial ACTREC, AIIMS, or a research-integrated private practice like Dr. Bharat Patodiya’s at Pi Cancer Care, where screening for active trials is a formal service.

What is the process for getting into a breast cancer clinical trial and how much does it cost?

Your current oncologist initiates a referral with your complete biopsy report, treatment history, and current performance status. A research coordinator screens these against strict eligibility criteria.

  • The investigational drug is typically sponsored and free.

  • However, you can still expect to pay for standard care costs like hospitalization and supportive medications unless subsidies apply.

What support services do cancer centers offer to help patients access clinical trials?

Dedicated patient navigators manage logistics, appointment scheduling, and travel coordination.

  • Financial counselors are available at most centers to verify your eligibility for government schemes, including Ayushman Bharat PM-JAY.

  • These counselors also coordinate charitable aid applications specifically for standard care bills that trials may not cover.

Does Pi Cancer Care have doctors who provide clinical trial access for stage 4 breast cancer?

Yes. Dr. Bharat Patodiya at Pi Cancer Care directly provides clinical trial access for stage 4 disease. His practice centers on eligibility screening, trial coordination, and providing transparent cost structures, where a clinical trial can save a patient ₹5 to 25 lakhs in treatment costs according to the center.

What are the eligibility criteria and safety considerations for joining a metastatic breast cancer trial?

Eligibility hinges on three main factors:

  • Your tumor's hormone and HER2 status.

  • The number and type of prior treatments you have received.

  • Your current organ function tests.

Safety is managed through a formal informed consent process explaining all grade 3/4 adverse event risks, like neutropenia or infusion reactions, specific to that investigational agent.

How much can clinical trial participation reduce the cost of cancer treatment in India?

Participation can substantially reduce costs by eliminating the price of the investigational drug itself, a saving that ranges from ₹5 to 25 lakhs depending on the agent and trial duration. You still bear standard care costs, but government hospitals like Tata Memorial can further reduce these by 50 to 70% through subsidies.

Sources

Comments

bottom of page